This week's biggest % winners & losers: July 13 - 17, 20 (wk 29)

 

The following are this week's top percentage gainers and losers, categorized by sectors (over $300 mln market cap and 100K average daily volume).

This week's top % gainers

• Healthcare: RIGL (3.24 +82.02%), MRNA (94.85 +51.49%), NVAX (140.49 +48.89%), THC (22.83 +28.4%), SGRY (14.61 +24.13%)
• Industrials: RUN (36.81 +27.41%), BE (16.99 +23.83%)
• Consumer Discretionary: HMHC (2.8 +75%), GTX (6.99 +38.14%), LRN (46.6 +37.34%), NEW (10.05 +27.7%), HBI (11.43 +22.66%)
• Information Technology: EIGI (6.03 +43.45%), RST (20.02 +25.6%)
• Energy: MMLP (2.02 +20.24%), NGL (4.28 +16.94%)

This week's top % losers

• Healthcare: GRTS (3.8 -53.03%), TCDA (16.5 -36.53%)
• Industrials: UPWK (13.94 -13.31%)
• Consumer Discretionary: NIO (11.09 -25.97%),  MOGU (3.38 -19.52%), UXIN (1.58 -10.23%)
• Information Technology: ECOM (14.88 -14.87%), CMCM (2.44 -11.59%), MODN (35.16 -9.4%), FTNT (129.12 -11.44%)
• Financials: NOAH (29.58 -14.61%), QD (2.04 -14.29%)

-=Rigel Pharma (RIGL) initiates a COVID-19 trial

Rigel Pharma and Imperial College London initiates two-stage trial to evaluate the efficacy of fostamatinib for the treatment of COVID-19 pneumonia

Announced the initiation of an investigator-sponsored trial being conducted by Imperial College London to evaluate the efficacy of oral SYK inhibitor fostamatinib for the treatment of COVID-19 pneumonia. The primary objective of the two-stage trial, which is to be supported by co and Novartis (NVS), will be to determine the efficacy of fostamatinib and of ruxolitinib vs standard of care.

=Long trade : RIGL +14% (4/18)

• April 11: #44, vol. 2.0M

RIGL — is it a buy?

a. Feb. 15: #37; Is RIGL a buy?

• 2 months later: NO